Evidence map›Paper›PMID 35045267›Full record

ArticleJournal of virology2022

Identification of a Permissive Secondary Mutation That Restores the Enzymatic Activity of Oseltamivir Resistance Mutation H275Y.

Li Jiang, Neha Samant, Ping Liu, Mohan Somasundaran, Jeffrey D Jensen, Wayne A Marasco, Timothy F Kowalik, Celia A Schiffer, Robert W Finberg, Jennifer P Wang and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Li JiangDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical Schoolgrid.168645.8, Worcester, Massachusetts, USA.
Neha SamantDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical Schoolgrid.168645.8, Worcester, Massachusetts, USA.
Ping LiuDepartment of Medicine, University of Massachusetts Medical Schoolgrid.168645.8, Worcester, Massachusetts, USA.ORCID 0000-0003-1309-570X
Mohan SomasundaranDepartment of Medicine, University of Massachusetts Medical Schoolgrid.168645.8, Worcester, Massachusetts, USA.
Jeffrey D JensenSchool of Life Sciences, Arizona State Universitygrid.215654.1, Tempe, Arizona, USA.
Wayne A MarascoDepartment of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Timothy F KowalikMicrobiology and Physiological Systems, University of Massachusetts Medical Schoolgrid.168645.8, Worcester, Massachusetts, USA.
Celia A SchifferDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical Schoolgrid.168645.8, Worcester, Massachusetts, USA.
Robert W FinbergDepartment of Medicine, University of Massachusetts Medical Schoolgrid.168645.8, Worcester, Massachusetts, USA.
Jennifer P WangDepartment of Medicine, University of Massachusetts Medical Schoolgrid.168645.8, Worcester, Massachusetts, USA.ORCID 0000-0002-2556-9100
Daniel N A BolonDepartment of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical Schoolgrid.168645.8, Worcester, Massachusetts, USA.ORCID 0000-0001-5857-6676
University of Massachusetts Chan Medical School · USArizona State University · USDana-Farber Cancer Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many oseltamivir resistance mutations exhibit fitness defects in the absence of drug pressure that hinders their propagation in hosts. Secondary permissive mutations can rescue fitness defects and facilitate the segregation of resistance mutations in viral populations. Previous studies have identified a panel of permissive or compensatory mutations in neuraminidase (NA) that restore the growth defect of the predominant oseltamivir resistance mutation (H275Y) in H1N1 influenza A virus. In prior work, we identified a hyperactive mutation (Y276F) that increased NA activity by approximately 70%. While Y276F had not been previously identified as a permissive mutation, we hypothesized that Y276F may counteract the defects caused by H275Y by buffering its reduced NA expression and enzyme activity. In this study, we measured the relative fitness, NA activity, and surface expression, as well as sensitivity to oseltamivir, for several oseltamivir resistance mutations, including H275Y in the wild-type and Y276F genetic background. Our results demonstrate that Y276F selectively rescues the fitness defect of H275Y by restoring its NA surface expression and enzymatic activity, elucidating the local compensatory structural impacts of Y276F on the adjacent H275Y.

Indexed as

Drug Resistance, ViralInfluenza A Virus, H1N1 SubtypeOseltamivirViral ProteinsAntiviral AgentsHumansInfluenza A virusInfluenza, HumanMutationNeuraminidaseAntiviral AgentsNeuraminidaseOseltamivirViral ProteinsH275Yinfluenza A virusneuraminidaseY276F

Identifiers

PMID35045267
PMCPMC8941911
OpenAlexW4205098952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.